AspirinStrokePlatelet Aggregation InhibitorsAnti-Inflammatory Agents, Non-SteroidalBrain IschemiaCerebrovascular DisordersTiclopidineThromboxane B2Fibrinolytic AgentsCyclooxygenase InhibitorsPlatelet AggregationRisk FactorsSalicylatesPlatelet Function TestsIschemic Attack, TransientAnticoagulantsProspective StudiesCerebral HemorrhageDrug Therapy, CombinationTreatment OutcomeWarfarinTime FactorsBlood PlateletsHemorrhageCerebral InfarctionFollow-Up StudiesSodium SalicylateAsthma, Aspirin-InducedIncidenceDouble-Blind MethodTablets, Enteric-CoatedAcute DiseaseThrombolytic TherapyThrombosisMyocardial InfarctionCohort StudiesCyclooxygenase 1Platelet ActivationTissue Plasminogen ActivatorBleeding TimeGastrointestinal HemorrhageRecurrenceDose-Response Relationship, DrugStroke, LacunarProstaglandin-Endoperoxide SynthasesThromboxanesDipyridamoleIbuprofenThromboxane A2Risk AssessmentStroke VolumeParesisAtrial FibrillationIntracranial HemorrhagesCyclooxygenase 2 InhibitorsRiskRecovery of FunctionCardiovascular DiseasesInfarction, Middle Cerebral ArteryAcetaminophenRandomized Controlled Trials as TopicLipoxinsBrain InfarctionSulfinpyrazoneDrug ResistanceRetrospective StudiesIndomethacinThromboembolismIntracranial EmbolismPrimary PreventionOdds RatioCyclooxygenase 2Secondary PreventionGastric MucosaSeverity of Illness IndexReye SyndromeStomach UlcerCase-Control StudiesProstaglandinsTomography, X-Ray ComputedAge FactorsHeparinNaproxenProportional Hazards Models